TipHub

326.79

+15.03 +4.82%

29 Jul 2026

NSE Listed · E-Commerce/App based Aggregator

LT-ASM · ASM 1
What does LT-ASM · ASM 1 mean?
BSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-24
NSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-24

Nureca Limited (NURECA)

Volume: 43,634Avg Vol 1W: 44,297Avg Vol 1M: 76,46152W Range:204343
Market Cap₹312 Cr
Current Price₹326.79
Previous Close₹311.76
High / Low (52w)₹343 / ₹204
Volume43,634
Avg Vol (1W)44,297
Avg Vol (1M)76,461
Stock P/E
Book Value₹189.48
Dividend Yield0%
ROE1.15%
ROA1.06%
Revenue (TTM)
Revenue Growth19.29%
Profit Margin1.42%
Total Debt₹1 Cr
Shares Outstanding1 Cr
Face Value₹10
EPS (TTM)₹-6.45
P/B1.72
Debt / Equity0.01
50 DMA₹255.41
200 DMA₹269.97
Day change+4.82%
SurveillanceLT-ASM · ASM 1
Price Chart
326.79 37.68% · 1Y
33320710.6L
2025-07-29
2026-07-29

20-day avg volume: 84K shares

Pros
  • Company is almost debt-free.
  • Revenue grew 14% YoY.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹31 Cr₹26 Cr₹32 Cr₹34 Cr₹38 Cr₹40 Cr₹35 Cr₹40 Cr
EBITDA₹0 Cr₹-3 Cr₹3 Cr₹1 Cr₹5 Cr₹5 Cr₹-5 Cr₹5 Cr
Net Profit₹0 Cr₹-3 Cr₹2 Cr₹1 Cr₹4 Cr₹4 Cr₹-6 Cr₹3 Cr
EPS
Profit & Loss (Annual)
MetricMar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026Jun 2026
Revenue₹32 Cr₹122 Cr₹34 Cr₹38 Cr₹40 Cr₹35 Cr₹155 Cr₹40 Cr
EBITDA₹2 Cr₹3 Cr₹1 Cr₹5 Cr₹4 Cr₹-6 Cr₹6 Cr₹4 Cr
Net Profit₹2 Cr₹1 Cr₹1 Cr₹3 Cr₹3 Cr₹-7 Cr₹2 Cr₹2 Cr
EPS0.852.11
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹24 Cr₹34 Cr₹186 Cr₹219 Cr₹207 Cr₹205 Cr₹210 Cr₹196 Cr
Total Liabilities₹16 Cr₹19 Cr₹23 Cr₹16 Cr₹12 Cr₹12 Cr₹16 Cr₹15 Cr
Equity₹8 Cr₹15 Cr₹163 Cr₹203 Cr₹195 Cr₹193 Cr₹194 Cr₹181 Cr
Total Debt
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹0 Cr₹-8 Cr₹50 Cr₹19 Cr₹14 Cr₹-4 Cr₹-18 Cr₹3 Cr
Investing₹0 Cr₹0 Cr₹-110 Cr₹-3 Cr₹-16 Cr₹18 Cr₹8 Cr₹14 Cr
Financing₹0 Cr₹8 Cr₹92 Cr₹-7 Cr₹-2 Cr₹-1 Cr₹0 Cr₹-20 Cr
Free Cash Flow₹0 Cr₹-8 Cr₹50 Cr₹19 Cr₹14 Cr₹-4 Cr₹-18 Cr₹3 Cr
Shareholding
Promoter 68.09% Institutions 0.34% Public 31.57%
Efficiency & Working Capital
ROCE0.3%
Interest Coverage4.9
Dividend Payout
Debtor Days19 d
Inventory Days118 d
Payable Days13 d
Cash Conversion Cycle125 d
Working Capital Days137 d
Shareholding Details

As of 2026-06-30

Promoter68.1%
FII0.1%
DII0.2%
Institutions0.3%
Public31.6%
Promoter Pledge0%
No. of Shareholders33,979
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodMar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Jan 2026Jan 2026Mar 2026Jun 2026
Promoters63.2%63.2%63.8%64.1%64.3%64.3%65%65%68.1%68.1%68.1%68.1%
FIIs0.1%0.1%0.7%0.4%1.1%0.1%0.1%0.1%0.1%0.1%0.3%0.1%
DIIs0%0%0%0%0%0%0%0%0%0%0.2%0.2%
Public36.7%36.7%35.5%35.5%34.6%35.6%34.9%34.9%31.8%31.8%31.4%31.6%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders45,99643,81341,98641,31439,30438,07537,46835,80135,80035,80034,55833,979
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603
Major Shareholders (>1%)
NameCategoryStakeShares
Saurabh GoyalShareholding of Promoter and Promoter Group34.4%32,78,056
Payal GoyalShareholding of Promoter and Promoter Group21.6%20,59,928
Aryan GoyalShareholding of Promoter and Promoter Group12.2%11,59,185
Nectar Biopharma Private LimitedShareholding of Promoter and Promoter Group0%0
Smita GoyalShareholding of Promoter and Promoter Group0%7
Board of Directors
NameDesignationYear
Saurabh GoyalChairman / Executive Director / Managing Director2026
Rajinder SharmaE D & Wholetime Director2026
Ruchita AgarwalIndependent Non Exe. Director2026
Charu SinghIndependent Non Exe. Director2026
V K SharmaIndependent Non Exe. Director2026
Rupinder TewariIndependent Non Exe. Director2026
Kuldip Kumar BhasinIndependent Non Exe. Director2026
Smita GoyalE D & Wholetime Director2026
Nishu KansalCompany Sec. & Compli. Officer2026
Segments — Product
SegmentRevenueShare
Home Healthcare and Wellness Produc₹0 Cr
Segments — Geography
RegionRevenueShare
India₹147 Cr99.9%
Outside India₹0 Cr0.1%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹10111010
Corporate Actions
TypeDateValueRemark
forthcoming2026-07-21Board Meetings
buyback2025-12-24₹330 max
forthcomingBook ClosureAGM
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
202685005092
202621000021
202664005071
Insider / Designated-Person Trades

2 recent disclosure(s)

Nectar Biopharma Private LimitedDisposal · 60,842
Saurabh GoyalAcquisition · 60,842
Substantial Acquisitions (SAST)

1 disclosure(s)

NULL01/07/2026 · 32,19,113
Company Information
Incorporated2016
ChairmanSaurabh Goyal
AuditorSinghi & Co
Investor Email[email protected]
🌐 www.nureca.com

📍 101 Gala Number Udyog Bhavan, I Flr Sonawala Lane Goregaon(E, Mumbai, Maharashtra, 400063

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search